Targeted-lung delivery of bardoxolone methyl using PECAM-1 antibody-conjugated nanostructure lipid carriers for the treatment of lung inflammation.

MLA

He, Jin-Xian, et al. “Targeted-Lung Delivery of Bardoxolone Methyl Using PECAM-1 Antibody-Conjugated Nanostructure Lipid Carriers for the Treatment of Lung Inflammation.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 178, Sept. 2024, p. 116992. EBSCOhost, https://doi.org/10.1016/j.biopha.2024.116992.

APA

He, J.-X., Zhu, C.-Q., Liang, G.-F., Mao, H.-B., Shen, W.-Y., & Hu, J.-B. (2024). Targeted-lung delivery of bardoxolone methyl using PECAM-1 antibody-conjugated nanostructure lipid carriers for the treatment of lung inflammation. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 178, 116992. https://doi.org/10.1016/j.biopha.2024.116992

Chicago

He, Jin-Xian, Chun-Qi Zhu, Gao-Feng Liang, Hai-Bo Mao, Wei-Yu Shen, and Jing-Bo Hu. 2024. “Targeted-Lung Delivery of Bardoxolone Methyl Using PECAM-1 Antibody-Conjugated Nanostructure Lipid Carriers for the Treatment of Lung Inflammation.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 178 (September): 116992. doi:10.1016/j.biopha.2024.116992.